Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study

Journal of Neurology

Volumn 262, Issue 5, 2015, Pages 1317-1327

  Matinella, Angela ^a   Lanzafame, M ^b   Bonometti, M A ^a   Gajofatto, A ^a   Concia, E ^b   Vento, S ^c   Monaco, S ^a   Ferrari, S ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Policlinico G Rossi   (Italy)

^c UNIVERSITY OF BOTSWANA   (Botswana)

Author keywords

Cryptococcal encephalitis; HIV; HIV associated neurocognitive disorder; Neurotoxoplasmosis; Primary central nervous system lymphoma; Progressive multifocal leukoencephalopathy

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA; IMMUNOGLOBULIN G;

ADULT; ARTICLE; BRAIN BIOPSY; BRAIN DAMAGE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCAL MENINGITIS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROLOGICAL COMPLICATION; NEUROTOXOPLASMOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OUTCOME ASSESSMENT; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETROSPECTIVE STUDY; SURVIVAL TIME; TOXOPLASMOSIS; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS LOAD; BLOOD; CD4+ T LYMPHOCYTE; CELL COUNT; COMPLICATION; GENETICS; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NONPARAMETRIC TEST; PATHOLOGY; PROCEDURES; SURVIVAL RATE; TOXOPLASMA; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NEUROIMAGING; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TOXOPLASMA; TREATMENT OUTCOME;

EID: 84929835431     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7713-8     Document Type: Article

References (61)

1. UNAIDS Global report (2010) UNAIDS report on the global AIDS epidemic, 2010. Geneva: Joint United Nation Programme on HIV/AIDS http://issuu.com/unaids/docs/unaids_globalreport_2010?e=2251159/2047939
2. UK Collaborative HIV Cohort (CHIC) Study Steering Committee, Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Phillips AN, Sabin CA (2011) HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol 18:527–534
3. d’Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J (2004) EuroSIDA Study Group. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 55:320–328
4. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC, Multicenter AIDS Cohort Study (2001) HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990–1998. Neurology 56:257–260
5. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799
6. Lindl KA, Marks DR, Kolson DL, Jordan-Sciutto KL (2010) HIV-Associated Neurocognitive Disorder: pathogenesis and Therapeutic Opportunities. J Neuroimmune Pharmacol 5:294–309
7. McArthur JC (2004) HIV dementia: an evolving disease. J Neuroimmunol 157:3–10
8. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, For the CHARTER Group (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. CHARTER study. Neurology 75:2087–2096
9. Clifford DB, Ances BM (2013) HIV-associated neurocognitive disorder. Lancet Infect Dis 13:976–986
10. Mocroft AJ, Lundgren JD, d’ArminoMonforte A, Ledergerber B, Barton SE, Vella S, Katlama C, Gerstoft J, Pedersen C, Phillips AN (1997) Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol 26:400–407
11. Centers for Disease Control and prevention (1993) Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. MMWR Recomm Rep 41:1–19
12. Portegies P, Enting RH, de Gans J, Algra PR, Derix MM, Lange JM, Goudsmit J (1993) Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS 7:669–675
13. Ammassari A, Scoppettuolo G, Murri R, Pezzotti P, Cingolani A, Del Borgo C, De Luca A, Antinori A, Ortona L (1998) Changing disease patterns in focal brain lesion-causing disorders in AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 18:365–371
14. Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE (1999) HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52:623–625
15. Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boué F, Billaud E, Costagliola D (1999) Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. AIDS 13:1881–1887
16. Ammassari A, Cingolani A, Pezzotti P, De Luca DA, Murri R, Giancola ML, Larocca LM, Antinori A (2000) AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 55:1194–1200
17. Maschke M, Kastrup O, Esser S, Ross B, Hengge U, Hufnagel A (2000) Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 69:376–380
18. Abgrall S, Rabaud C, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV (2001) Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis 33:1747–1755
19. Berenguer J, Miralles P, Arrizabalaga J, Ribera E, Dronda F, Baraia-Etxaburu J, Domingo P, Márquez M, Rodriguez-Arrondo FJ, Laguna F, Rubio R, Lacruz Rodrigo J, Mallolas J, de Miguel V, GESIDA 11/99 Study Group (2003) Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 36:1047–1052
20. Antinori A, Larussa D, Cingolani A, Lorenzini P, Bossolasco S, Finazzi MG, Bongiovanni M, Guaraldi G, Grisetti S, Vigo B, Gigli B, Mariano A, Dalle Nogare ER, De Marco M, Moretti F, Corsi P, Abrescia N, Rellecati P, Castagna A, Mussini C, Ammassari A, Cinque P, d’Arminio Monforte A (2004) Italian Registry Investigative NeuroAIDS. Prevalence, associated factors, and prognostic determinants of aids-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis 39:1681–1691
21. Diamond C, Taylor TH, Im T, Miradi M, Wallace M, Anton-Culver H (2006) Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin’s lymphoma. Curr HIV Res 4:375–378
22. Lipman M, Breen R (2006) Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis 19:20–25
23. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S (2007) The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 165:1143–1153
24. Falcó V, Olmo M, del Saz SV, Guelar A, Santos JR, Gutiérrez M, Colomer D, Deig E, Mateo G, Montero M, Pedrol E, Podzamczer D, Domingo P, Llibre JM (2008) Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 49:26–31
25. Shiels MS, Cole SR, Kirk GD, Poole C (2009) A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52:611–622
26. Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, Kesari S, Berger JR, Simpson DM, Prosperi M, De Luca A, Koralnik IJ (2009) Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 73:1551–1558
27. Tambussi G, Gori A, Capiluppi B, Balotta C, Papagno L, Morandini B, Di Pietro M, Ciuffreda D, Saracco A, Lazzarin A (2000) Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis 30:962–965
28. Christo PP, Greco DB, Aleixo AW, Livramento JA (2005) HIV-1 RNA levels in cerebrospinal fluid and plasma and their correlation with opportunistic neurological diseases in a Brazilian AIDS reference hospital. Arq Neuropsiquiatr 63:907–913
29. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, Peytavin G, Tubiana R, Pialoux G, Katlama C (2010) Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 50:773–778
30. Luft BJ, Brooks RG, Conley FK, McCabe RE, Remington JS (1984) Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA 252:913–917
31. Torok ME (2005) Human immunodeficiency virus associated central nervous system infection. Practical Neurology 5:334–3494
32. Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW (2009) Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 9:625–636
33. Riveiro-Barciela M, Falcó V, Burgos J, Curran A, Van den Eynde E, Navarro J, Villar del Saz S, Ocaña I, Ribera E, Crespo M, Pahissa A (2013) Neurological opportunistic infections and neurological immune reconstitution syndrome: impact of one decade of highly active antiretroviral treatment in a tertiary hospital. HIV Med 14:21–30
34. Tan K, Roda R, Ostrow L, McArthur J, Nath A (2009) PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72:1458–1464
35. González-Scarano F, Martín-García J (2005) The neuropathogenesis of AIDS. J Nat Rev Immunol 5:69–81
36. Janssen RS, Cornblath DR, Epstein LG et al (1991) Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 41:778–785
37. Mind Exchange Working Group (2013) Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 56:1004–1017
38. Valcour VG (2011) Evaluating cognitive impairment in the clinical setting: practical screening and assessment tools. Top Antivir Med 19:175–180
39. Overton ET, Kauwe JS, Paul R, Tashima K, Tate DF, Patel P, Carpenter CC, Patty D, Brooks JT, Clifford DB (2011) Performances on the CogState and standard neuropsychological batteries among HIV patients without dementia. AIDS Behav 15:1902–1909
40. Overton ET, Azad TD, Parker N, Demarco Shaw D, Frain J, Spitz T, Westerhaus E, Paul R, Clifford DB, Ances BM (2013) The Alzheimer’s disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons. J Neurovirol 19:109–116
41. Chalermchai T, Valcour V, Sithinamsuwan P, Pinyakorn S, Clifford D, Paul RH, Tipsuk S, Fletcher JL, Degruttola V, Ratto-Kim S, Hutchings N, Shikuma C, Ananworanich J, SEARCH 007 and 011 study groups (2013) Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND. J Neurovirol 19:137–143
42. Ellis RJ, Evans SR, Clifford DB, Moo LR, McArthur JC, Collier AC, Benson C, Bosch R, Simpson D, Yiannoutsos CT, Yang Y, Robertson K, Neurological AIDS Research Consortium; AIDS Clinical Trials Group Study Teams A5001 and A362 (2005) Clinical validation of the neuroscreen. J Neurovirol 11:503–511
43. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK (1992) Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 42:1472–1476
44. McArthur J, Grant I (1998) HIV neurocognitive disorders. In: Gendelman H, Lipton S, Epstein L, Swindells S (eds) The Neurology of AIDS. International Thompson Publishing, New York, pp 499–523
45. McArthur JC, Steiner J, Sacktor N, Nath A (2010) Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 67:699–714
46. Stout JC, Ellis RJ, Jernigan TL, Archibald SL, Abramson I, Wolfson T, McCutchan JA, Wallace MR, Atkinson JH, Grant I, HIV Neurobehavioral Research Center Group (1998) Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. Arch Neurol 55:161–168
47. Küper M, Rabe K, Esser S, Gizewski ER, Husstedt IW, Maschke M, Obermann M (2011) Structural gray and white matter changes in patients with HIV. J Neurol 258:1066–1075
48. Devlin KN, Gongvatana A, Clark US, Chasman JD, Westbrook ML, Tashima KT, Navia B, Cohen RA (2012) Neurocognitive effects of HIV, hepatitis C, and substance use history. J Int Neuropsychol Soc 18:68–78
49. Zhang L, Looney D, Taub D, Chang SL, Way D, Witte MH, Graves MC, Fiala M (1998) Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirol 4:619–626
50. Silverstein PS, Shah A, Weemhoff J, Kumar S, Singh DP, Kumar A (2012) HIV-1 gp120 and drugs of abuse: interactions in the central nervous system. Curr HIV Res 10:369–383
51. Buch S, Yao H, Guo M, Mori T, Mathias-Costa B, Singh V, Seth P, Wang J, Su TP (2012) Cocaine and HIV-1 interplay in CNS: cellular and molecular mechanisms. Curr HIV Res 10:425–428
52. Clifford DB, Evans SR, Yang Y, Gulick RM (2005) The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS 19(suppl 3):S64–S71
53. Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes K, Thomas HC, Taylor-Robinson SD (2005) A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS 19(Suppl 3):S53–S63
54. Cherner M, Letendre S, Heaton RK, Durelle J, Marquie-Beck J, Gragg B, Grant I, HIV Neurobehavioral Research Center Group (2005) Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 64:1343–1347
55. Hilsabeck RC, Castellon SA, Hinkin CH (2005) Neuropsychological aspects of coinfection with HIV and hepatitis C virus. Clin Infect Dis 41(suppl 1):S38–S44
56. Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P (2004) Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 62:957–962
57. Forton DM, Hamilton G, Allsop JM, Grover VP, Wesnes K, O’Sullivan C, Thomas HC, Taylor-Robinson SD (2008) Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. J Hepatol 49:316–322
58. Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, Penalva de Oliveira AC, Pumpradit W, Shlay JC, El-Sadr W, Price RW, INSIGHT SMART Study Group (2010) Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 75:864–873
59. Becker JT, Kingsley L, Mullen J, Cohen B, Martin E, Miller EN, Ragin A, Sacktor N, Selnes OA, Visscher BR (2009) Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 73:1292–1299
60. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, Letendre SL, Ellis RJ, Heaton RK, Wolfson T, Rosario D, Alexander TJ, Marra C, Ances BM, Grant I, For the CHARTER Group (2012) Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology 78:485–492
61. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525–530